Iniparib plus Chemotherapy in Metastatic Triple-Negative Breast Cancer
The DOI matches its Crossref record; 31 of the 32 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Triple-negative breast cancers have inherent defects in DNA repair, making this cancer a rational target for therapy based on poly(adenosine diphosphate-ribose) polymerase (PARP) inhibition. METHODS: We conducted an open-label, phase 2 study to compare the efficacy and safety of gemcitabine and carboplatin with or without iniparib, a small molecule with PARP-inhibitory activity, in patients with metastatic triple-negative breast cancer. A total of 123 patients were randomly assigned to receive gemcitabine (1000 mg per square meter of body-surface area) and carboplatin (at a dose equivalent to an area under the concentration-time curve of 2) on days 1 and 8--with or without iniparib (at a dose of 5.6 mg per kilogram of body weight) on days 1, 4, 8, and 11--every 21 days. Primary end points were the rate of clinical benefit (i.e., the rate of objective response [complete or partial response] plus the rate of stable disease for ≥6 months) and safety. Additional end points included the rate of objective response, progression-free survival, and overall survival. RESULTS: The addition of iniparib to gemcitabine and carboplatin improved the rate of clinical benefit from 34% to 56% (P=0.01) and the rate of overall response from 32% to 52% (P=0.02). The addition of iniparib also prolonged the median progression-free survival from 3.6 months to 5.9 months (hazard ratio for progression, 0.59; P=0.01) and the median overall survival from 7.7 months to 12.3 months (hazard ratio for death, 0.57; P=0.01). The most frequent grade 3 or 4 adverse events in either treatment group included neutropenia, thrombocytopenia, anemia, fatigue or asthenia, leukopenia, and increased alanine aminotransferase level. No significant difference was seen between the two groups in the rate of adverse events. CONCLUSIONS: The addition of iniparib to chemotherapy improved the clinical benefit and survival of patients with metastatic triple-negative breast cancer without significantly increased toxic effects. On the basis of these results, a phase 3 trial adequately powered to evaluate overall survival and progression-free survival is being conducted. (Funded by BiPar Sciences [now owned by Sanofi-Aventis]; ClinicalTrials.gov number, NCT00540358.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The oncology literature has indicated that positive phase II data are not necessarily replicated in the phase III setting”
In the citing paper
“Furthermore, ongoing clinical trials for metastatic TNBC are including platinum agents in their treatment regimens (4, 36–38).”
From Potentiation of carboplatin-mediated DNA damage by the Mdm2 modulator Nutlin-3a in a humanized orthotopic breast-to-lung metastatic model (2015) · cites this paper as [36]
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., McFadden, E. T., & Carbone, P. P. (1982) · AMERICAN JOURNAL OF CLINICAL ONCOLOGY · doi:10.1097/00000421-198212000-00014 · Cited by 11,647
Sørlie, T., Perou, C. M., Tibshirani, R., Aas, T., Geisler, S., Johnsen, H., Hastie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191367098 · Cited by 10,938
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
Repeated observation of breast tumor subtypes in independent gene expression data sets
Sørlie, T., Tibshirani, R., Parker, J., Hastie, T., Marron, J. S., Nobel, A., Deng, S., Johnsen, H., Pesich, R., Geisler, S., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0932692100 · Cited by 5,429
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., & Helleday, T. (2005) · Nature · doi:10.1038/nature03443 · Cited by 5,198
Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes
Parker, J. S., Mullins, M., Cheang, M. C. U., Leung, S., Voduc, D., Vickery, T., Davies, S., Fauron, C., He, X., Hu, Z., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.1370 · Cited by 4,721
Race, Breast Cancer Subtypes, and Survival in the Carolina Breast Cancer Study
Carey, L. A., Perou, C. M., Livasy, C. A., Dressler, L. G., Cowan, D., Conway, K., Karaca, G., Troester, M. A., Tse, C. K., Edmiston, S., et al. (2006) · JAMA · doi:10.1001/jama.295.21.2492 · Cited by 3,819
Audeh, M. W., Carmichael, J., Penson, R. T., Friedlander, M., Powell, B., Bell-McGuinn, K. M., Scott, C., Weitzel, J. N., Oaknin, A., Loman, N., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60893-8 · Cited by 2,279
Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy
Rouzier, R., Perou, C. M., Symmans, W. F., Ibrahim, N., Cristofanilli, M., Anderson, K., Hess, K. R., Stec, J., Ayers, M., Wagner, P., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2421 · Cited by 1,891
Cited by
Items 801–876 of 876
Galvis-Jiménez, J. M. (2020) · Gredos (University of Salamanca) · doi:10.14201/gredos.145512
(2013) · CRC Press eBooks · doi:10.1201/b14587-16
Balboni, A. (2021) · AMS Dottorato Institutional Doctoral Theses Repository (University of Bologna) · doi:10.6092/unibo/amsdottorato/9587
Harbeck, N., & Sotlar, K. (2014) · best practice onkologie · doi:10.1007/s11654-013-0111-8
Targeting Self-renewal Pathways in Cancer Stem Cells
Maugeri‐Saccà, M., & Zeuner, A. (2012) · Springer eBooks · doi:10.1007/978-94-007-2900-1_3
2011 Publications of the Baylor Health Care System Medical and Scientific Staff
(2012) · Baylor University Medical Center Proceedings · doi:10.1080/08998280.2012.11928826
(2013) · CRC Press eBooks · doi:10.1201/b14587-15
Enrichments of Ensemble Docking Strategy Based on the Bayesian ModelPreprint
Yu, L., Guo, S. H., Liu, Y., & Zuo, Z. (2021) · doi:10.21203/rs.3.rs-138297/v1
Hertz, D. L., & McLeod, H. L. (2015) · Wiley-VCH eBooks · doi:10.1002/3527600906.mcb.201500002
Hodgson, S. V., Foulkes, W. D., Eng, C., & Maher, E. R. (2013) · Springer eBooks · doi:10.1007/978-1-4471-2375-0_6
Kelly, K. (2011) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.11241956.12228054
Re: Potential Pitfalls of Crossover and Thoughts on Iniparib in Triple-Negative Breast Cancer
Kane, R. C. (2012) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djs164
Oncology: Biochemists’ Perspective
Pal, D., & Panda, C. K. (2022) · Springer eBooks · doi:10.1007/978-981-16-4752-9_9
Liu, X., Wu, K., Zheng, D., Luo, C., Fan, Y., Zhong, X., & Zheng, H. Y. (2020) · Research Square · doi:10.21203/rs.3.rs-116023/v1
Met‐Domestici, M., & Murphy, A. E. (2019) · Principles of specialty nursing · doi:10.1007/978-3-319-76457-3_25
Big data analytics and cancer biology: lessons in taking science from the processor to the patient
Borcherding, N. C., Zhan, F., Tanas, M. R., Weigel, R. J., Zhang, W., & Dupuy, A. J. (2020) · doi:10.17077/etd.005280
Mateo, J., Yap, T. A., & Bono, J. S. D. (2014) · Current clinical urology · doi:10.1007/978-1-4939-1176-9_18
Khong, H. T. (2011) · Current Biomarker Findings · doi:10.2147/cbf.s18327
Biologisch stratifizierte Therapie
Sicking, I., & Schmidt, M. (2015) · gynäkologie + geburtshilfe · doi:10.1007/s15013-015-0597-y
(2011) · Annals of Oncology · doi:10.1093/annonc/mdr102
Loi, S. (2019) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.733400528.793562861
Role of Biomarkers in Clinical Development of Cancer Therapies
Chen, H. (2013) · Pan Stanford Publishing eBooks · doi:10.1201/b15029-4
Targeted Molecular Therapy for Ovarian Cancer Patients
Farghaly, S. A. (2022) · Springer eBooks · doi:10.1007/978-3-031-09169-8_11
Küemmel, S., Campone, M., Loirat, D., López‐López, R., Beck, J. T., Laurentiis, M. D., Im, S., Kim, S., Kwong, A., Steger, G. G., et al. (2023) · doi:10.1158/1078-0432.c.6530927
Xie, X., Lee, J., Liu, H., Pearson, T., Lu, A., Tripathy, D., Devi, G. R., Bartholomeusz, C., & Ueno, N. T. (2023) · doi:10.1158/1535-7163.c.6542818
Systemic chemotherapy for metastatic breast cancer
Zhao, Y., & Wang, B. (2015) · Oncology and Translational Medicine · doi:10.1007/s10330-014-0048-6
Inibidores da PARP para o câncer de mama triplo negativo: Uma revisão de literatura
Pinheiro, A. M., Magalhães, A. L. B., Saddi, V. A., & Ribeiro, A. A. (2023) · Research Society and Development · doi:10.33448/rsd-v12i6.42367
Büyükşimşek, M., Tohumcuoğlu, M., Sedef, A. M., Bahçeci, A., Nayır, E., Yılmaz, M., Temi, Y. B., Beşen, A. A., Diker, Ö., Şimşek, M., et al. (2022) · Akademisyen Kitabevi eBooks · doi:10.37609/akya.1538
Triple-Negative and Basal-like Carcinoma
Dabbs, D. J. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-38961-7.00024-1
(2014) · The MIT Press eBooks · doi:10.7551/mitpress/9796.003.0011
Reducing O-GlcNAcylation sensitizes breast cancer cells to lapatinib
Ashraf, A., & McGonigle, P. (2014) · iDEA - Drexel University Institutional Repository · doi:10.17918/00009635
Vukea, N., Oderinlo, O. O., Tukulula, M., Khanye, S. D., Edkins, A. L., & de la Mare, J. (2025) · PLoS ONE · doi:10.1371/journal.pone.0328155
AVANÇOS EM TERAPIAS-ALVO NO CÂNCER DE MAMA COM MUTAÇÕES HER2 E BRCA: PERSPECTIVAS E DESAFIOS
Melo, B. C., Lima, R. F. D. S., de Souza, A. L. M., Aguiar, A. B., & Fernandes, N. P. D. C. (2025) · Revista Brasileira de Saúde · doi:10.22533/at.ed.8208162501107
DNA Repair System: The Important Role in Cancers
Wirasorn, K., & Punjaruk, W. (2013) · Srinagarind Medical Journal (SMJ) - ศรีนครินทร์เวชสาร
Beuzeboc, P. (2014)
Inhibiteurs de PARP et radiothérapie
Bollet, M. A., Pouzoulet, F., Mégnin-Chanet, F., Favaudon, V., & Hall, J. A. (2012) · ONCOLOGIE · doi:10.1007/s10269-012-2115-8
Id1 as a prospective marker for cancer stem cells in triple-negative breast cancer
Ye, S. Y. S. (2013) · UNSWorks (UNSW Sydney) · doi:10.26190/unsworks/16543
Tesch, H., Lüftner, D., Wormann, B. J., Onkologie, D. G. F. H. U. M., & Bundesausschuss, D. G. (2018) · PUBLISSO (German National Library of Medicine) · doi:10.4126/frl01-006426160
Additional file 1 of Racial disparities in breast cancer preclinical and clinical models
Clarke, S., Chin, S. N., Dodds, L., George, S. H. L., & Badal, S. (2022) · Figshare · doi:10.6084/m9.figshare.20444349
Additional file 2 of Racial disparities in breast cancer preclinical and clinical models
Clarke, S., Chin, S. N., Dodds, L., George, S. H. L., & Badal, S. (2022) · Figshare · doi:10.6084/m9.figshare.20444352
Theilhaber, J., Chiron, M., Dreymann, J., Bergstrom, D., & Pollard, J. (2020) · Figshare · doi:10.6084/m9.figshare.12720247
Theilhaber, J., Chiron, M., Dreymann, J., Bergstrom, D., & Pollard, J. (2020) · Figshare · doi:10.6084/m9.figshare.12720259
Theilhaber, J., Chiron, M., Dreymann, J., Bergstrom, D., & Pollard, J. (2020) · Figshare · doi:10.6084/m9.figshare.12720232
Identifikation molekularer Targets für die Therapie des triple-negativen Mammakarzinoms
Mumm, J.-N. (2020) · Elektronische Hochschulschriften der LMU München (Ludwig-Maximilians-Universität München) · doi:10.5282/edoc.26202
Mun, S. G., Choi, H. W., Lee, J. M., Lim, J. H., Ha, J. H., Kang, M.-J., Kim, E.-J., Kang, L., & Chung, B. G. (2020) · Figshare · doi:10.6084/m9.figshare.11992551
Lluch Hernández, A. (2011) · Repository of Digital Objects for Teaching Research and Culture (University of Valencia)
Croteau, É. (2011) · Knowledge UdeS (Institutional Deposit of the University of Sherbrooke)
深澤, 和. (2015) · Institutional Repositories DataBase (IRDB)
Mendo, A. S. (2013) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
Maleki, M., & Ghahari, S. A. (2025) · Preprints.org · doi:10.20944/preprints202509.0178.v1
Interaction between stem cells from amniotic membrane and canine mammary tumor in vitro
Borghesi, J. (2019) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
Li, J., Cui, Y., Xiong, M., Zhang, L., Mu, S., He, Z., Zhu, H., Yang, K., & Zhong, Q. (2026) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2026.109507
Ayme, A. (2013) · theses.fr (ABES) · doi:10.70675/9e63b493z9591z4b85zb3d5zb41ad5fbfe7a
抗がん剤の国内承認審査の傾向分析とトリプルネガティブ乳癌の代替エンドポイントの妥当性評価 ~新規抗がん剤の早期開発・早期承認と第三次予防の促進を目指して~
岳大, 平. (2022) · Institutional Repositories DataBase (IRDB)
Salvador, M. A. (2014) · theses.fr (ABES) · doi:10.70675/e6271213z23d6z45e2z8558z016ac2e02ef3
Mechanism of ubiquitylation in DNA damage response
Kumbhar, R. (2016) · theses.fr (ABES) · doi:10.70675/fed94622z133az437dz9d6ezeee63d950c74
Bouaouiche, S. (2018) · theses.fr (ABES) · doi:10.70675/85185e48z640cz4823z8ea3z8f24dc88fcdd
Investigations de nouvelles stratégies de radio-marquage aux isotopes de l'iode.
Bloux, H. (2022) · theses.fr (ABES) · doi:10.70675/2ed29e64za67fz44ffzb5b6z2af4f7872b2b
Wagoner, C. M. V., Kitelinger, L. E., DeWitt, M. R., Conarroe, C. A., Kim, A., Streit, A. B., Price, R. J., & Bullock, T. N. J. (2026) · Cells · doi:10.3390/cells15111035
An Investigation of the Anti-Cancer Effects of Apple Flavonoids Fraction 4 on Breast Cancer Cells
Loung, C.-Y. (2018) · DalSpace (Dalhousie University)
Javad, M. (2017) · DalSpace (Dalhousie University)
Evaluation of overall survival in cancer phase 3 clinical trials
SHOGO, N., ショウゴ, ノ., & SHOGO, N. (2020) · Institutional Repositories DataBase (IRDB)
Gupta, P., Solanki, R., Patel, M., Deb, S., Vashistha, R., & Sharma, A. (2021) · International Journal of Health and Clinical Research
Bhadange Jyoti, A., & Kokate, S. V. (2026) · Asian Journal of Pharmaceutical Research and Development
Katsiki-Gkivalou, A. (2025) · ΙΝΣΤΙΤΟΥΤΟ ΙΣΤΟΡΙΚΩΝ ΕΡΕΥΝΩΝ (National Hellenic Research Foundation)
Lou, S., Wang, Y., Zhang, J., Yin, X., Zhang, Y., Wang, Y., & Xue, Y. (2022) · doi:10.3389/fimmu.2021.806324.s004
Use of rHuG-CSF in New Chemotherapy Strategies
Renwick, W. E. P. (2011) · Springer eBooks · doi:10.1007/978-3-0348-0218-5_13
Novel targeted agents in Her-2 positive and triple negative breast cancer
Tryfonopoulos, D. J. (2013) · Dublin City University Open Access Institutional Repository (Dublin City University)
Base excision repair of radiation-induced DNA damage in mammalian cells
Cooper, S. L. P., & Cooper, S. (2013) · Oxford University Research Archive (ORA) (University of Oxford) · doi:10.5287/ora-4jbdj9zje
Role of Poly ADP-Ribose Polymerase (PARP) Inhibitors in Triple-Negative Breast Cancer (TNBC)
Ricevuto, E., Cannita, K., Bruera, G., Palluzzi, E., Cocciolone, V., Ficorella, C., & Russo, A. D. (2015) · Current clinical pathology · doi:10.1007/978-1-4939-2047-1_7
Metadata
- Authors
- O'Shaughnessy, J., Osborne, C., Pippen, J. E., Yoffe, M., Patt, D., Rocha, C., Koo, I. C., Sherman, B. M., & Bradley, C.
- Affiliations
- Texas Oncology (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2011-01-20
- Volume
- 364
- Issue
- 3
- Pages
- 205-214
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2111429259
- Cited by
- 817
- References
- 32
- Citations by year
- 2026: 3 · 2025: 11 · 2024: 6 · 2023: 22 · 2022: 23 · 2021: 30 · 2020: 27 · 2019: 30 · 2018: 47 · 2017: 52 · 2016: 42 · 2015: 72 · 2014: 90 · 2013: 94 · 2012: 133
- FWCI
- 70.91
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Keywords
- metastatic triple-negative breast cancer, PARP inhibition, gemcitabine, carboplatin, combination chemotherapy, DNA repair deficiency, clinical benefit, progression-free survival, overall survival, adverse events, neutropenia, thrombocytopenia, drug safety and efficacy
- MeSH terms
- Poly(ADP-ribose) Polymerase Inhibitors, Gemcitabine, Adolescent, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Benzamides, Breast Neoplasms, Deoxycytidine, Female, Humans, Neoplasm Metastasis, Survival Analysis, Carboplatin, Cross-Over Studies, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.